Positive New Data For Olesoxime
Drug Discovery & Development | November 24, 2010
Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced that Trophos and partners in the MS-Repair consortium delivered an oral presentation detailing Trophos’ novel approach in multiple sclerosis (MS) at the recent Society for Neuroscience (SfN) Meeting. The data presented demonstrate that olesoxime, Trophos’ lead compound, is a promising candidate for neuroaxonal repair and remyelination in white matter diseases, notably multiple sclerosis. The MS-Repair project is supported by the French Agence Nationale pour la Recherche (ANR).
Click HERE or on the image below to read more…
SMAHeadlines.com 